All In Biotech

Drug Trial Radar · NCT07205887

A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO

A Phase 2 Randomized, Dose-Masked Study of Intravitreal EYE103 in Participants With Neovascular Age-Related Macular Degeneration (NVAMD) or Macular Edema Following Branch Retinal Vein Occlusion (BRVO)

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Sep 12, 2025

Primary completion

Jun 30, 2028

Study completion Jun 30, 2028

Sponsor

Lead sponsor
EyeBiotech Ltd.Industry
Sponsor type
Industry
First posted
Oct 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

EYE-RES-104 is a randomized, dose-masked study of intravitreal remigromig (EYE103) in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO). The study will consist of 4 patient cohorts, with participants in each cohort randomized (1:1) to either a low dose of remigromig via IVT or a high dose of remigromig via IVT. 40 participants will be enrolled in each cohort. Enrollment timing for each cohort will be sequenced into specific arms of the study at the Sponsor's discretion. All participants in the study will receive a total of 3 injections of remigromig into the study eye, spaced at 4 weeks apart. All participants will return at designated time points following each injection for safety and efficacy assessments. The Week 12 Visit will serve as the end of study visit for all participants.

Conditions

  • Neovascular Age-Related Macular Degeneration (NVAMD)
  • Branch Retinal Vein Occlusion (BRVO)

Interventions

  • RemigromigDrug

    Remigromig is a humanized antibody formulated for intravitreal administration

  • Aflibercept 2.0 mgDrug

    Aflibercept 2.0 mg is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with Neovascular Age-Related Macular Degeneration (NVAMD). Aflibercept 2.0 mg is only administered to 2 cohorts of Incomplete Responders (IR) with NVAMD in combination with Low Dose or High Dose Remigromig.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Best-Corrected Visual Acuity measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chartTime frame: Week 12

Locations

55 sites in 1 country. Site status is shown where the registry gives one.

  • Scottsdale, Arizona

    Scottsdale, Arizona · Recruiting

  • Scottsdale, AZ

    Scottsdale, Arizona · Recruiting

  • Glendale, California

    Glendale, California · Recruiting

  • Glendale, CA

    Glendale, California · Recruiting

  • Modesto, California

    Modesto, California · Recruiting

  • Mountain View, California

    Mountain View, California · Recruiting

  • Sacramento, CA

    Sacramento, California · Recruiting

  • Sactamento, California

    Sacramento, California · Recruiting

  • Sacramento, California

    Sacramento, California · Recruiting

  • Santa Ana, California

    Santa Ana, California · Recruiting

  • RSC Research LLC

    Denver, Colorado · Recruiting

  • Fort Lauderdale, Florida

    Fort Lauderdale, Florida · Recruiting

  • Fort Lauderdale, FL

    Fort Lauderdale, Florida · Recruiting

  • Florida Retina Institute

    Jacksonville, Florida · Recruiting

  • Florida Retina Institute

    Orlando, Florida · Recruiting

  • Lemont, Illinois

    Lemont, Illinois · Recruiting

  • Lemont, IL

    Lemont, Illinois · Recruiting

  • Hagerstown, Maryland

    Hagerstown, Maryland · Recruiting

  • Hagerstown, MD

    Hagerstown, Maryland · Recruiting

  • Madison, Mississippi

    Madison, Mississippi · Recruiting

  • Madison, MS

    Madison, Mississippi · Recruiting

  • Bloomfield, New Jersey

    Bloomfield, New Jersey · Recruiting

  • Bloomfield, NJ

    Bloomfield, New Jersey · Recruiting

  • Long Island Vitreoretinal Consultants of NY

    Great Neck, New York · Recruiting

  • Asheville, North Carolina

    Asheville, North Carolina · Recruiting

  • Cary, North Carolina

    Cary, North Carolina · Recruiting

  • North Carolina Retina Associates

    Greenville, North Carolina · Recruiting

  • Wake Forest, NC

    Wake Forest, North Carolina · Recruiting

  • Wake Forest, North Carolina

    Wake Forest, North Carolina · Recruiting

  • West Columbia, SC

    West Columbia, South Carolina · Recruiting

  • West Columbia, South Carolina

    West Columbia, South Carolina · Recruiting

  • Germantown, Tennessee

    Germantown, Tennessee · Recruiting

  • Knoxville, Tennessee

    Knoxville, Tennessee · Recruiting

  • Nashville, Tennessee

    Nashville, Tennessee · Recruiting

  • Nashville, TN

    Nashville, Tennessee · Recruiting

  • Abilene, Texas

    Abilene, Texas · Recruiting

  • Amarillo, Texas

    Amarillo, Texas · Recruiting

  • Austin, Texas

    Austin, Texas · Recruiting

  • Austin, TX

    Austin, Texas · Recruiting

  • Bellaire, Texas

    Bellaire, Texas · Recruiting

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.